awmsg logo



everolimus (Afinitor®)


Reference No. 142

Publication date:
13/08/2012


Last review date:
30/08/2016

Appraisal information

everolimus (Afinitor®) tablet


Company: Novartis Pharmaceuticals UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 12/06/2012
AWMSG meeting date: 18/07/2012
   
   
Submission Type: Full Submission
Status: Superseded
Advice No: 2112
Ministerial ratification: 07/08/2012

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA449) NICE GUIDANCE ISSUED JUNE 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download